Abstract

Tumor xenograft models can create a high capacity to study human tumors and discover efficient therapeutic approaches. Here, we aimed to develop the gamma-radiated immunosuppressed (GIS) mice as a new kind of tumor xenograft model for biomedical studies. First, 144 mice were divided into the control and treated groups exposed by a medical Cobalt-60 apparatus in 3, 4, and 5 Gy based on the system outputs. Then, 144 BALB/c mice were divided into four groups; healthy, xenograft, radiation, and radiation + xenograft groups. The animals in the xenograft and radiation + xenograft groups have subcutaneously received 3 × 106 MCF-7 cells 24 h post-radiation. On 3, 7, 14, and 21 days after cell injection, the animals were sacrificed. Then, the blood samples and the spleen and tumor tissues were removed for the cellular and molecular analyses. The whole-body gamma radiation had a high immunosuppressive effect on the BALB/c mice from 1 to 21 days post-radiation. The macroscopic and histopathological observations have proved that the created clusters' tumor structure resulted in the xenograft breast tumor. There was a significant increase in tumor size after cell injection until the end of the study. Except for Treg, the spleen level of CD4, CD8, CD19, and Ly6G was significantly decreased in Xen + Rad compared to the Xen alone group on 3 and 7 days. Unlike IL-4 and IL-10, the spleen level of TGF-β, INF-γ, IL-12, and IL-17 was considerably decreased in the Xen + Rad than the Xen alone group on 3 and 7 days. The spleen expressions of the VEGF, Ki67, and Bax/Bcl-2 ratio were dramatically increased in the Xen + Rad group compared to the Xen alone on 3, 7, 14, and 21 days. Our results could confirm a new tumor xenograft model via an efficient immune-suppressive potential of the whole-body gamma radiation in mice.

Details

Title
RETRACTED ARTICLE: Gamma-radiated immunosuppressed tumor xenograft mice can be a new ideal model in cancer research
Author
Khodayari, Hamid 1 ; Khodayari, Saeed 2 ; Khalighfard, Solmaz 3 ; Tahmasebifar, Arash 4 ; Tajaldini, Mahboubeh 4 ; Poorkhani, Amirhoushang 4 ; Nikoueinejad, Hassan 5 ; Hamidi, Gholam Ali 6 ; Nosrati, Hassan 7 ; Kalhori, Mohammad Reza 8 ; Alizadeh, Ali Mohammad 9 

 Kashan University of Medical Sciences, Physiology Research Center, Kashan, Iran (GRID:grid.444768.d) (ISNI:0000 0004 0612 1049); Tehran University of Medical Sciences, Radiation Oncology Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
 Tehran University of Medical Sciences, Radiation Oncology Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922); Tehran University of Medical Sciences, Cancer Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
 Tehran University of Medical Sciences, Cancer Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
 Golestan University of Medical Sciences, Ischemic Disorder Center, Gorgan, Iran (GRID:grid.411747.0) (ISNI:0000 0004 0418 0096) 
 Baqiyatallah University of Medical Sciences, Nephrology and Urology Research Center, Tehran, Iran (GRID:grid.411521.2) (ISNI:0000 0000 9975 294X) 
 Kashan University of Medical Sciences, Physiology Research Center, Kashan, Iran (GRID:grid.444768.d) (ISNI:0000 0004 0612 1049) 
 Tehran University of Medical Sciences, Radiation Oncology Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
 Kermanshah University of Medical Sciences, Medical Biology Research Center, Kermanshah, Iran (GRID:grid.412112.5) (ISNI:0000 0001 2012 5829) 
 Tehran University of Medical Sciences, Cancer Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922); Tehran University of Medical Sciences, Breast Disease Research Center, Tehran, Iran (GRID:grid.411705.6) (ISNI:0000 0001 0166 0922) 
Pages
256
Publication year
2021
Publication date
2021
Publisher
Nature Publishing Group
e-ISSN
20452322
Source type
Scholarly Journal
Language of publication
English
ProQuest document ID
2890172495
Copyright
© The Author(s) 2021. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.